Last reviewed · How we verify
HBM9036 0.25% Ophthalmic Solution
HBM9036 0.25% Ophthalmic Solution is a C5a receptor antagonist Small molecule drug developed by Harbour BioMed (Guangzhou) Co. Ltd.. It is currently in Phase 3 development for Dry eye disease.
HBM9036 is a small-molecule inhibitor of the C5a receptor that reduces complement-mediated inflammation in the eye.
HBM9036 is a small-molecule inhibitor of the C5a receptor that reduces complement-mediated inflammation in the eye. Used for Dry eye disease.
At a glance
| Generic name | HBM9036 0.25% Ophthalmic Solution |
|---|---|
| Sponsor | Harbour BioMed (Guangzhou) Co. Ltd. |
| Drug class | C5a receptor antagonist |
| Target | C5aR (C5a receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
HBM9036 selectively blocks the C5a complement receptor (C5aR), preventing the recruitment and activation of inflammatory cells in ocular tissues. By inhibiting this key step in the complement cascade, the drug reduces inflammatory cytokine production and tissue damage in the eye. This mechanism is particularly relevant for dry eye disease and other ocular surface inflammatory conditions.
Approved indications
- Dry eye disease
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
Key clinical trials
- A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye (PHASE3)
- A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBM9036 0.25% Ophthalmic Solution CI brief — competitive landscape report
- HBM9036 0.25% Ophthalmic Solution updates RSS · CI watch RSS
- Harbour BioMed (Guangzhou) Co. Ltd. portfolio CI
Frequently asked questions about HBM9036 0.25% Ophthalmic Solution
What is HBM9036 0.25% Ophthalmic Solution?
How does HBM9036 0.25% Ophthalmic Solution work?
What is HBM9036 0.25% Ophthalmic Solution used for?
Who makes HBM9036 0.25% Ophthalmic Solution?
What drug class is HBM9036 0.25% Ophthalmic Solution in?
What development phase is HBM9036 0.25% Ophthalmic Solution in?
What are the side effects of HBM9036 0.25% Ophthalmic Solution?
What does HBM9036 0.25% Ophthalmic Solution target?
Related
- Drug class: All C5a receptor antagonist drugs
- Target: All drugs targeting C5aR (C5a receptor)
- Manufacturer: Harbour BioMed (Guangzhou) Co. Ltd. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye disease
- Compare: HBM9036 0.25% Ophthalmic Solution vs similar drugs
- Pricing: HBM9036 0.25% Ophthalmic Solution cost, discount & access